Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInvestment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

MediWound (MDWD) EBITDA: 2013-2025

Historic EBITDA for MediWound (MDWD) over the last 13 years, with Sep 2025 value amounting to -$2.7 million.

  • MediWound's EBITDA rose 74.14% to -$2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.0 million, marking a year-over-year increase of 139.06%. This contributed to the annual value of -$30.2 million for FY2024, which is 349.06% down from last year.
  • MediWound's EBITDA amounted to -$2.7 million in Q3 2025, which was down 119.96% from $13.3 million recorded in Q2 2025.
  • MediWound's 5-year EBITDA high stood at $13.3 million for Q2 2025, and its period low was -$10.3 million during Q3 2024.
  • Over the past 3 years, MediWound's median EBITDA value was -$2.2 million (recorded in 2023), while the average stood at -$1.3 million.
  • Over the last 5 years, MediWound's EBITDA had its largest YoY gain of 588.10% in 2024, and its largest YoY loss of 370.03% in 2024.
  • Quarterly analysis of 5 years shows MediWound's EBITDA stood at -$4.2 million in 2021, then plummeted by 80.00% to -$7.5 million in 2022, then spiked by 76.54% to -$1.8 million in 2023, then slumped by 122.58% to -$3.9 million in 2024, then surged by 74.14% to -$2.7 million in 2025.
  • Its EBITDA stands at -$2.7 million for Q3 2025, versus $13.3 million for Q2 2025 and -$725,000 for Q1 2025.